TruScreen Awarded Zimbabwe Tender

NZX/ASX Announcement

6 November 2023


TruScreen Awarded Zimbabwe Tender


Truscreen Group Limited (NZX/ASX:TRU) is pleased to confirm the receipt of a further purchase order
from Zimbabwe for SUS (single use sensor) with a gross sales value of approximately NZ$300,000.
The SUS is the disposal consumable item used in each TruScreen cervical cancer screening test.
Zimbabwe, under the auspices of the National Aids Council (NAC) program have already screened a
total of 14,000 women in Masvingo province. It is expected that this initial program will be extended
to a national roll out.
Cervical cancer is the most prevalent and deadly cancer for women in Zimbabwe
1
. Women living with
HIV have a six-fold increased risk of cervical cancer, when compared to women without HIV
2
. As part
of the national screening project, and the ongoing partnership with NAC, TruScreen cervical cancer
screening forms part of routine screening for the general population, and for women living with HIV.

The CEO, Dr Beata Edling commented:
“This new purchase order from Zimbabwe is confirmation that TruScreen is making a difference in
ensuring that early treatment for cervical cancer significantly reduces the potential downstream health
and human costs. We commend our distributor Southern Skies Medical Pvt Ltd and NAC for their
ongoing support in this program”.

This announcement has been approved by the Board.

Ends

For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com





1
Data source: GLOBCAN 2020, International Agency for Research on Cancer 2021
2
Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer
associated with HIV. Lancet Glob Health 2020. doi:S2214-109X(20)30459-9.

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical
cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the
TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and
COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the
Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a
manufacturing facility in China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and
Cervical Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In financial year 2023 alone, over 140000* examinations have been performed
with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam,
Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical
cancer”
©
.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special
brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is
sent to a laboratory for a pathologist to examine under a microscope. https://www.cancer.net/navigating-
cancer-care/diagnosing-cancer/tests-and-procedures/pap-test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto
a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at
the same time, such as the human papillomavirus (HPV) test https://www.cancer.net/cancer-types/cervical-
cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample
used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical
cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done
on a sample of cells which a person can collect on their own.
https://www.cancer.net/cancer-types/cervical-
cancer/screening-and-prevention

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence or
absence of a condition. If individuals who have the condition are considered "positive" and those who don't
are considered "negative", then sensitivity is a measure of how well a test can identify true positives and
specificity is a measure of how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test result, conditioned on the
individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result, conditioned on the
individual truly being negative (Sensitivity and specificity – Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia,
please see useful links:
New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)

Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council